Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment

Shanghai Green Valley Pharma announced China approval of Oligomannate, a seaweed-based treatment for Alzheimer's disease that improves cognitive function. In a China clinical trial, patients who received Oligomannate showed a mean gain of 2.54 in their ADAS-Cog12 Scores, a result that was consistent from the first month to the end of the treatment at nine months. Oligomannate, a low molecular acid oligosaccharide compound extracted from marine brown algae, is the first new treatment for Alzheimer's globally since 2003, and also one of the first approved drugs that works by modifying the gut microbiome. Green Valley will launch the drug in China before the end of 2019 and start global Phase III trials next year to support approval in the US, Europe and Asia. More details....

Share this with colleagues: